2015年2月27日 · FBXW7, a substrate-targeting subunit of the SCF (Skp1–Cul1–F box) ubiquitin ligase complex 20, targets several key regulators of proliferation, growth and apoptosis for proteasomal degradation ...

2023年3月18日 · FBXW7 is a main tumor suppressor due to its ability to control proteasome-mediated degradation of several oncoproteins such as c-Jun, c-Myc, Cyclin E1, mTOR, and Notch1-IC. FBXW7 inactivation...

2025年2月3日 · In this study, we report that FBXW7 mediates the ubiquitination and degradation of PRR11 through the GSK3β-mediated phosphorylation of PRR11 at Thr287, Ser291, Thr326, and Thr330. Furthermore, we demonstrated the important role of the AKT-GSK3β axis in preventing FBXW7-mediated PRR11 degradation.

28424-1-AP targets FBXW7 in WB, IHC, IF, IP, ELISA applications and shows reactivity with Human, Mouse samples. PBS with 0.02% sodium azide and 50% glycerol pH 7.3. Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA.

2022年1月12日 · IP results obtained using HA-FBXW7 and these expression vectors showed that mutation of ERK3 Thr417 and Thr421 to alanine (Myc-ERK3-FL-mtPDM2) dramatically reduced its interaction with FBXW7...

We reported here that FBXW7 directly binds to RbBP5 among other five components of KMT2 complex, identified by IP-coupled mass spectrometry, in multiple human cancer cells and MEFs under the physiological condition, as well as in vitro using purified proteins.

2 天之前 · 3月12日，美国密西根大学和浙江大学的孙毅教授课题组与现任陆军军医大学西南医院的谢传明教授在Cell Reports发表了题为The FBXW7-SHOC2-Raptor axis controls the cross-talks between the RAS/ERK and mTORC1 signaling pathways的文章，报道了FBXW7通过泛素化降解SHOC2来调控RAS/ERK与mTORC1两种 ...

2025年2月11日 · A follow-up immunoprecipitation (IP) assay confirmed the interaction of endogenous RPAP2 with wild-type FBXW7 but not with the FBXW7 R479L mutant in HEK293 cells (Figure S3B, Supporting Information), suggesting that RPAP2 is a candidate FBXW7 interacting substrate protein.

- **治疗方法的影响**：FBXW7突变的 转移性结直肠癌 患者在使用针对EGFR的疗法时，疾病进展更快，表明FBXW7可能是抗EGFR疗法反应的负向调节因子。

结果表明，FBXW1与ACC、BLCA、BRCA、PCPG、UCEC和UCS中具有代表性的免疫检查点呈负相关。 然而，在大多数癌症中，FBXW7与这些免疫检查点呈正相关。 FBXW1和FBXW7在免疫浸润中的相反关系可能是癌症患者预后不同的原因。